Enanta Pharmaceuticals (ENTA) Cash from Investing Activities Growth (1y) (2013 - 2026)
Enanta Pharmaceuticals (ENTA) Cash from Investing Activities Growth (1y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 90.55% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 91.53% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.90% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7,936.68% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 26.37% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -157.08% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -89.24% |
| 10 | Enanta Pharmaceuticals | 383.29 Mn | 193.78 Mn | - | 152.88% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 152.88% |
| Mar 31, 2026 | 373.33% |
| Dec 31, 2025 | -168.64% |
| Sep 30, 2025 | -87.96% |
| Jun 30, 2025 | -317.38% |
| Mar 31, 2025 | -107.45% |
| Dec 31, 2024 | 625.30% |
| Sep 30, 2024 | 61.14% |
| Jun 30, 2024 | 95.65% |
| Mar 31, 2024 | 25.36% |
| Dec 31, 2023 | -139.07% |
| Sep 30, 2023 | -58.07% |
| Jun 30, 2023 | -998.57% |
| Mar 31, 2023 | 233.40% |
| Dec 31, 2022 | -26.22% |
| Sep 30, 2022 | -61.16% |
| Jun 30, 2022 | 137.11% |
| Mar 31, 2022 | -237.70% |
| Dec 31, 2021 | 360.83% |
| Sep 30, 2021 | 2,802.68% |